ORGS
Orgenesis Inc.Company Information
- Company Name
- Orgenesis Inc.
- CIK
- CIK0001460602
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ORGS: None
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ORGS
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-06-24
- Last sale
- 2024-06-24
- Shares purchased (TTM)
- 25,100
- Shares sold (TTM)
- 10,000
Institutional Sentiment
- As of
- 2025-03-31
- Institutional shares owned
- 50,623
- Shares outstanding
- 4,210,839
- Ownership
- 1.20%
Earnings Market Reaction
- Filing date
- 2026-03-26
- Price on filing date
- —
- 1-month reaction
- -68.00%
- 3-month reaction
- -1.00%
Balance Sheet
Values in millions ($)| Line item | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 5 | 3 | 2 | 1 | ||||||
| Restricted Cash Current | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 36 | 24 | 19 | 17 | ||||||
| Due From Related Parties Current | - | - | - | - | - | - | - | - | 3 | - | - | - | ||||||
| Other Receivables Net Current | - | - | - | - | - | - | - | 3 | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 0 | 1 | 1 | 1 | 2 | 4 | 4 | 5 | 1 | 1 | 1 | 1 | ||||||
| Notes And Loans Receivable Net Current | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Inventory Net | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 1 | 3 | 2 | 2 | 4 | 6 | 7 | 30 | 46 | 32 | 25 | 24 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Investments | - | - | - | - | - | - | - | - | - | 2 | 2 | 2 | ||||||
| Deposits Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Long Term Investments | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | ||||||
| Property Plant And Equipment Net | 1 | 15 | 16 | 16 | 1 | 2 | 1 | 22 | 23 | 17 | 14 | 11 | ||||||
| Intangible Assets Net Excluding Goodwill | - | 9 | 9 | 9 | 7 | 8 | 8 | 9 | 10 | 11 | 11 | 12 | ||||||
| Operating Lease Right Of Use Asset | - | 2 | 2 | 2 | 0 | 0 | 0 | 3 | 2 | 1 | 1 | 1 | ||||||
| Goodwill | - | 1 | 1 | 1 | 1 | 1 | 1 | 8 | 8 | 8 | 8 | 8 | ||||||
| Deferred Income Tax Assets Net | - | - | - | - | - | - | - | 0 | 0 | - | - | - | ||||||
| Other Assets Noncurrent | - | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets Noncurrent | 1 | 27 | 28 | 29 | 10 | 12 | 12 | 44 | 45 | 39 | 37 | 35 | ||||||
| Assets | 1 | 30 | 31 | 31 | 15 | 18 | 18 | 74 | 91 | 71 | 63 | 59 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | - | - | - | - | - | - | - | 4 | 4 | 5 | 5 | 7 | ||||||
| Bank Overdrafts | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Accrued Liabilities Current | 2 | 3 | 3 | 4 | 2 | 2 | 2 | 3 | 3 | - | - | - | ||||||
| Accrued Income Taxes Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
| Employee Related Liabilities Current | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | ||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Loans Payable Current | 6 | - | - | - | 1 | - | - | - | - | - | - | - | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | ||||||
| Other Liabilities Current | - | - | - | - | - | - | - | 2 | 5 | 22 | - | - | ||||||
| Convertible Debt Current | - | - | - | - | - | 3 | - | - | - | - | 6 | 3 | ||||||
| Short Term Borrowings | 6 | 5 | 1 | 1 | 1 | 0 | - | - | - | - | - | - | ||||||
| Convertible Notes Payable Current | 2 | 2 | 2 | 2 | 3 | - | 2 | - | 5 | - | - | - | ||||||
| Liabilities Current | 27 | 36 | 32 | 29 | 16 | 14 | 13 | 14 | 16 | 34 | 16 | 15 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 2 | 2 | 1 | 0 | 0 | ||||||
| Long Term Loans Payable | 3 | 3 | 3 | 3 | - | - | - | - | - | - | - | - | ||||||
| Convertible Debt Noncurrent | 6 | 5 | 5 | 20 | 19 | 18 | 18 | 17 | 13 | 5 | 14 | 8 | ||||||
| Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent | - | 0 | 0 | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Finance Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities Noncurrent | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Noncurrent | 12 | 18 | 15 | 29 | 19 | 19 | 18 | 20 | 16 | 6 | 15 | 8 | ||||||
| Liabilities | 39 | 54 | 46 | 58 | 36 | 33 | 31 | 34 | 32 | 40 | 31 | 24 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Redeemable Noncontrolling Interest Equity Carrying Amount | - | - | - | - | - | - | - | 30 | 30 | - | - | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 188 | 182 | 181 | 160 | 157 | 156 | 155 | 151 | 150 | 149 | 147 | 146 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | -0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -1 | -0 | 0 | ||||||
| Treasury Stock Value | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -225 | -204 | -195 | -186 | -177 | -170 | -166 | -141 | -121 | -117 | -116 | -110 | ||||||
| Stockholders Equity | -38 | -24 | -16 | -28 | -21 | -15 | -13 | 10 | 28 | 30 | 32 | 35 | ||||||
| Minority Interest | -0 | -0 | -0 | 0 | - | - | - | 1 | 2 | 0 | 0 | 0 | ||||||
| Liabilities And Stockholders Equity | 1 | 30 | 31 | 31 | 15 | 18 | 18 | 74 | 91 | 71 | 63 | 59 | ||||||
| Accounts Receivable Related Parties Current | - | - | - | - | - | - | - | - | - | 2 | 2 | 2 | ||||||
| Allowance For Doubtful Accounts Receivable | - | - | - | - | - | - | - | 9 | - | - | - | - | ||||||
| Allowance For Doubtful Accounts Receivable Current | 14 | 14 | 29 | 30 | 0 | 0 | 0 | - | 0 | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 15 | 15 | 146 | 146 | 15 | 146 | 146 | 146 | 146 | 146 | 146 | 146 | ||||||
| Common Stock Shares Issued | 5 | 5 | 5 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Shares Outstanding | 5 | 5 | 5 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | ||||||
| Treasury Stock Shares | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialOrgenesis Inc. (ORGS) — SEC Financial Statements & Analysis
Orgenesis Inc. (ORGS) is a pharmaceutical preparations company, incorporated in NV. Orgenesis Inc. trades on None as: ORGS. Orgenesis Inc. (ORGS)'s most recent SEC filing is a Form 10-K for the period ended 2024-12-31, filed with the SEC on 2026-03-26. Based on its latest SEC filing (Form 10-Q, period ending 2024-12-31), Orgenesis Inc. carries a market cap of $7.96M, a P/E ratio of 0.16x, a P/B ratio of -0.21x, a P/S ratio of 7.69x, an enterprise value of $27.85M, and an EV/EBITDA multiple of 0.67x. On profitability, it posts a gross margin of -86.28%, an operating margin of 3842.32%, a net margin of 4735.56%, a Return on Equity (ROE) of -167.52%, a Return on Assets (ROA) of 616.40%, and a Return on Invested Capital (ROIC) of 244.05%. Per share, it reports EPS of $11.64, diluted EPS of $11.64, free cash flow per share of $-4.12, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 95.28% year-over-year, net income growth of -11.47% year-over-year, and EPS growth of -39.01% year-over-year. On the balance sheet, it maintains a current ratio of 0.03x, a quick ratio of 0.03x, working capital of $-26.16M, a debt-to-equity ratio of -1.04x, a debt ratio of 28.78, free cash flow of $-17.34M (TTM), and net debt of $19.89M. Figures sourced from SEC EDGAR.
- Market Cap
- $7.96M
- P/E TTM
- 0.16x
- EPS TTM
- $11.64
- P/B TTM
- -0.21x
- ROE TTM
- -167.52%
- ROA TTM
- 616.40%
- Debt To Equity
- -1.04x
- Free Cash Flow TTM
- $-17.34M
- Net Revenue TTM Growth 1Y
- 95.28%
Data as of 2024-12-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Orgenesis Inc. in?
Orgenesis Inc. (ORGS) operates in the Pharmaceutical Preparations industry.
What exchange does ORGS trade on?
Orgenesis Inc. (ORGS) trades on the None.
Where is Orgenesis Inc. incorporated?
Orgenesis Inc. is incorporated in NV.
When was Orgenesis Inc. (ORGS)'s most recent SEC filing?
Orgenesis Inc. (ORGS)'s most recent SEC filing is a Form 10-K for the period ended 2024-12-31, filed with the SEC on 2026-03-26.
What is ORGS's market cap?
Orgenesis Inc. (ORGS) has a market capitalization of $7.96M as of 2024-12-31.
What is ORGS's P/E ratio?
Orgenesis Inc. (ORGS)'s trailing twelve month P/E ratio is 0.16x as of 2024-12-31.
What is ORGS's EPS (earnings per share)?
Orgenesis Inc. (ORGS)'s trailing twelve month EPS is $11.64 as of 2024-12-31.
What is ORGS's ROE (return on equity)?
Orgenesis Inc. (ORGS)'s trailing twelve month Return on Equity (ROE) is -167.52% as of 2024-12-31.
What is ORGS's ROA (return on assets)?
Orgenesis Inc. (ORGS)'s trailing twelve month Return on Assets (ROA) is 616.40% as of 2024-12-31.
What is ORGS's ROIC (return on invested capital)?
Orgenesis Inc. (ORGS)'s trailing twelve month Return on Invested Capital (ROIC) is 244.05% as of 2023-12-31.
What is ORGS's EV/EBITDA?
Orgenesis Inc. (ORGS)'s trailing twelve month EV/EBITDA is 0.67x as of 2024-12-31.